With at least two in three Australians diagnosed with skin cancer before the age of 70, monitoring moles and skin is vital in detecting skin cancer early for a generation of people who spent much of their upbringing in the sun (often with little to no protection).
To meet the massive unmet need in this area, Research Professor at UniSA’s Future Industries Institute, Professor Tarl Prow led the team that has created a new needle device that will revolutionise how doctors test patients for rashes and diseases.
The microbiopsy device is a small needle that can take 100 to 200 cells to test for skin cancer and other diseases avoiding the need to take a 2cm to 3cm piece of tissue which results in some scarring.
Dr Prow says the device can take skin samples much more easily than a traditional biopsy and is easy and painless to use on children.
“The innovation for this device comes from the idea of a diabetic test. We can easily take small skin samples which makes it much easier to use on children and allows us to take multiple samples over time to monitor a patient’s situation,” Prof Prow says.
“Given a standard biopsy is a significant procedure, we wanted to help make that process easier.”
The device has already proved a possible game changer in underprivileged countries with doctors from Jerusalem’s Hebrew University already taking 502 units to Africa to use in the field.
“With many parasitic diseases in Africa, where people don’t have access to a hospital, researchers at Hebrew University undertook a study in northern Ethiopia testing hundreds of children and adults using the device,” he says.
With skin cancer a more prevalent problem in Australia, doctors can spend up a significant amount of time checking a patient’s skin (including moles and pink spots) and Dr Prow and his team are working on developing cancer biomarkers, so the device can take samples and evaluate (and reveal) the results instantly.
With clinical trials (unrelated to skin cancer) in the final stages, the team is monitoring feedback with thousands of devices already sold worldwide and is patented in the US, Australia and Europe.
“We are planning to test the efficacy and safety for microbiopsy in skin cancer diagnosis that will start in early 2019 so some patients may be asked to be a part of this study. We hope to launch the approved diagnostic test in 2023,” Dr Prow says.
The Latest on: Microbiopsy
via Google News
The Latest on: Microbiopsy
Microbiopsy Needle for Pain- and Scar-free Skin Sampling
on April 17, 2018 at 2:29 am
A painless, scar-free biopsy method offers a less invasive approach to collecting skin samples for the diagnosis Source: Tarl Prow, University of South Australiaof cancer and other diseases. The microbiopsy needle designed at the University of South ... […]
Microbiopsy device samples skin cells for cancer without scarring
on April 13, 2018 at 12:53 am
Skin cancer is the most common form of the disease, and while it might make its presence known in the form of moles or strange spots, it usually takes a biopsy to confirm whether the mark is malignant or not. Now, an Australian team has developed a ... […]
New microbiopsy device could revolutionize testing for skin cancer, other diseases
on April 10, 2018 at 12:30 am
With at least two in three Australians diagnosed with skin cancer before the age of 70, monitoring moles and skin is vital in detecting skin cancer early for a generation of people who spent much of their upbringing in the sun (often with little to no ... […]
New needle device to revolutionise biopsies and reduce scarring
on April 6, 2018 at 6:57 am
The microbiopsy device is a small needle that can take 100 to 200 cells to test for skin cancer and other diseases avoiding the need to take a 2cm to 3cm piece of tissue which results in some scarring. Dr. Prow says the device can take skin samples much ... […]
MYOS RENS inks deal with University of California to study effects of Fortetropin on skeletal muscle protein synthetic rate
on December 6, 2017 at 4:45 pm
After 21 days, a microbiopsy will be collected from each subject to determine the fractional rate of muscle protein synthesis. The clinical study is expected to be completed in the H2 2018. Fortetropin is the all-natural food ingredient clinically shown to ... […]
LEO Science & Tech Hub Announces Collaborations with MGH Wellman Center for Photomedicine to Explore Imaging Technology and Develop Microbiopsy Device
on August 23, 2017 at 1:30 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LEO Science & Tech Hub, a R&D unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases, today announced two collaborative projects with ... […]
Capture of activity-induced ultrastructural changes at synapses by high-pressure freezing of brain tissue
on May 28, 2014 at 5:00 pm
Figure 2: Punching and placement of slice culture onto specimen carrier. Figure 4: Fine structure of microbiopsy material and of acute slice preparations following HPF. Figure 5: Post-embedding immunogold labeling of thin sections from slice cultures for p ... […]
All atypia diagnosed at stereotactic vacuum-assisted breast biopsy do not need surgical excision
on February 15, 2011 at 4:00 pm
E-mail: [email protected] The aim of our study is to account for these issues by defining criteria on which to base the decision of whether or not to excise when atypia are diagnosed by microbiopsy, by comparing mammographical data (with experienced ... […]
Laboratory Freezer aids with sample preparation.
on April 11, 2006 at 5:00 pm
The EM RTS can also be used to enhance the speed of taking a biopsy in conjunction with the Leica's new Microbiopsy Transfer System. With a turn-around time of 30 seconds for the EM PACT2, samples can be frozen at twice the rate of other high-pressure ... […]
via Bing News